Recent Finacing
Recent Raise
Alumis is a clinical-stage biopharmaceutical company developing precision oral TYK2 inhibitors (ESK-001, A-005) and leveraging a multi-platform analytics system combining genetic, clinical, and EHR data for target and patient-selection.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
